Abstract:Abstract Background Heterogeneous nuclear ribonucleoprotein K (HnRNPK) is a nucleic acid-binding protein that regulates diverse biological events. Pathologically, HnRNPK proteins are frequently overexpressed and clinically correlated with poor prognosis in various types of human cancers and are therefore pursued as attractive therapeutic targets for select patients. However, both the transcriptional regulation and degradation of HnRNPK in prostate cancer remain poorly understood. Methods qRT-PCR was used to detect the expression of HnRNPK mRNA and miRNA; Immunoblots and immunohistochemical assays were used to determine the levels of HnRNPK and other proteins. Flow cytometry was used to investigate cell cycle stage. MTS and clonogenic assays were used to investigate cell proliferation. Immunoprecipitation was used to analyse the interaction between SPOP and HnRNPK. A prostate carcinoma xenograft mouse model was used to detect the in vivo effects of HnRNPK and miRNA. Results In the present study, we noted that HnRNPK emerged as an important player in the carcinogenesis process of prostate cancer. miR-206 and miR-613 suppressed HnRNPK expression by targeting its 3’-UTR in PrCa cell lines in which HnRNPK is overexpressed. To explore the potential biological function, proliferation and colony formation of PrCa cells in vitro and tumor growth in vivo were also dramatically suppressed upon reintroduction of miR-206/miR - 613. We have further provided evidence that Cullin 3 SPOP is a novel upstream E3 ubiquitin ligase complex that governs HnRNPK protein stability and oncogenic functions by promoting the degradation of HnRNPK in polyubiquitination-dependent proteolysis in the prostate cancer setting. Moreover, prostate cancer-associated SPOP mutants fail to interact with and promote the destruction of HnRNPK proteins. Conclusion Our findings reveal new posttranscriptional and posttranslational modification mechanisms of HnRNPK regulation via miR-206/miR - 613 and SPOP, respectively. More importantly, given the critical oncogenic role of HnRNPK and the high frequency of SPOP mutations in prostate cancer, our results provide a molecular rationale for the clinical investigation of novel strategies to combat prostate cancer based on SPOP genetic status.

Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer

SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression

Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP–HIPK2 axis

Prostate Cancer-Associated Mutation in SPOP Impairs Its Ability to Target Cdc20 for Poly-Ubiquitination and Degradation.

Destruction of DDIT3/CHOP Protein by Wild-Type SPOP but Not Prostate Cancer-Associated Mutants

Identification of SPOP Related Metabolic Pathways in Prostate Cancer.

SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer

Enhanced autophagy and NFE2L2/NRF2 pathway activation in SPOP mutation-driven prostate cancer

SPOP Inhibits BRAF-dependent Tumorigenesis Through Promoting Non-Degradative Ubiquitination of BRAF

Prostate Cancer-associated SPOP Mutations Enhance Cancer Cell Survival and Docetaxel Resistance by Upregulating Caprin1-dependent Stress Granule Assembly.

The diverse roles of SPOP in prostate cancer and kidney cancer

SPOP point mutations regulate substrate preference and affect its function

[Identification of Speckle Type BTB/POZ Protein Mutation Regulated Key Metabolic Pathways by Cell Based Proteomics and Metabolomics].

Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover

Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4

SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1–PD-L1 axis

TGF-β signaling regulates SPOP expression and promotes prostate cancer cell stemness

Endometrial Cancer-Associated Mutants of SPOP Are Defective in Regulating Estrogen Receptor-Α Protein Turnover.

Intrinsic BET Inhibitor Resistance in SPOP-mutated Prostate Cancer is Mediated by BET Protein Stabilization and AKT–mTORC1 Activation

Transcriptional regulation and ubiquitination-dependent regulation of HnRNPK oncogenic function in prostate tumorigenesis